tetano
Editor, Senior Moderator
Rev Med Virol
. 2020 Sep 18;e2161.
doi: 10.1002/rmv.2161. Online ahead of print.
Covid-19 and dengue: Double punches for dengue-endemic countries in Asia
Harapan Harapan[SUP] 1 2 3 [/SUP], Mirza Ryan[SUP] 1 [/SUP], Benediktus Yohan[SUP] 4 [/SUP], Rufika Shari Abidin[SUP] 5 [/SUP], Firzan Nainu[SUP] 6 [/SUP], Ahmed Rakib[SUP] 7 [/SUP], Israt Jahan[SUP] 8 [/SUP], Talha Bin Emran[SUP] 9 [/SUP], Irfan Ullah[SUP] 10 [/SUP], Kritu Panta[SUP] 11 [/SUP], Kuldeep Dhama[SUP] 12 [/SUP], R Tedjo Sasmono[SUP] 4 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (Covid-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an international public health crisis with devastating effects. In particular, this pandemic has further exacerbated the burden in tropical and subtropical regions of the world, where dengue fever, caused by dengue virus (DENV), is already endemic to the population. The similar clinical manifestations shared by Covid-19 and dengue fever have raised concerns, especially in dengue-endemic countries with limited resources, leading to diagnostic challenges. In addition, cross-reactivity of the immune responses in these infections is an emerging concern, as pre-existing DENV-antibodies might potentially affect Covid-19 through antibody-dependent enhancement. In this review article, we aimed to raise the issue of Covid-19 and dengue fever misdiagnosis, not only in a clinical setting but also with regards to cross-reactivity between SARS-CoV-2 and DENV antibodies. We also have discussed the potential consequences of overlapping immunological cascades between dengue and Covid-19 on disease severity and vaccine development.
Keywords: ADE; Covid-19; SARS-CoV-2; cross-reactivity; dengue.
. 2020 Sep 18;e2161.
doi: 10.1002/rmv.2161. Online ahead of print.
Covid-19 and dengue: Double punches for dengue-endemic countries in Asia
Harapan Harapan[SUP] 1 2 3 [/SUP], Mirza Ryan[SUP] 1 [/SUP], Benediktus Yohan[SUP] 4 [/SUP], Rufika Shari Abidin[SUP] 5 [/SUP], Firzan Nainu[SUP] 6 [/SUP], Ahmed Rakib[SUP] 7 [/SUP], Israt Jahan[SUP] 8 [/SUP], Talha Bin Emran[SUP] 9 [/SUP], Irfan Ullah[SUP] 10 [/SUP], Kritu Panta[SUP] 11 [/SUP], Kuldeep Dhama[SUP] 12 [/SUP], R Tedjo Sasmono[SUP] 4 [/SUP]
Affiliations
- PMID: 32946149
- DOI: 10.1002/rmv.2161
Abstract
The coronavirus disease 2019 (Covid-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an international public health crisis with devastating effects. In particular, this pandemic has further exacerbated the burden in tropical and subtropical regions of the world, where dengue fever, caused by dengue virus (DENV), is already endemic to the population. The similar clinical manifestations shared by Covid-19 and dengue fever have raised concerns, especially in dengue-endemic countries with limited resources, leading to diagnostic challenges. In addition, cross-reactivity of the immune responses in these infections is an emerging concern, as pre-existing DENV-antibodies might potentially affect Covid-19 through antibody-dependent enhancement. In this review article, we aimed to raise the issue of Covid-19 and dengue fever misdiagnosis, not only in a clinical setting but also with regards to cross-reactivity between SARS-CoV-2 and DENV antibodies. We also have discussed the potential consequences of overlapping immunological cascades between dengue and Covid-19 on disease severity and vaccine development.
Keywords: ADE; Covid-19; SARS-CoV-2; cross-reactivity; dengue.